Tyra Biosciences To Host Conference Call On Interim Clinical Data Of TYRA-300 From SURF301 Phase 1/2 Study On October 25, 2024, At 8:00 am ET
Portfolio Pulse from Benzinga Newsdesk
Tyra Biosciences (NASDAQ:TYRA) will host a conference call on October 25, 2024, to discuss interim clinical data of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer. The data will also be presented at the ENA Symposium in Barcelona.
October 23, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tyra Biosciences is set to release interim clinical data for TYRA-300, which could significantly impact its stock price. The data will be shared in a conference call and at a major symposium, indicating its potential importance.
The announcement of interim clinical data for TYRA-300 is a significant event for Tyra Biosciences, as it could influence investor perception and stock price. The presentation at a major symposium further underscores the importance of these results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100